Research analysts at UBS Group initiated coverage on shares of Inventiva (NASDAQ:IVA - Get Free Report) in a report issued on Tuesday, Marketbeat.com reports. The brokerage set a "neutral" rating and a $3.00 price target on the stock. UBS Group's target price would suggest a potential upside of 11.94% from the stock's previous close.
A number of other equities research analysts have also recently weighed in on the company. HC Wainwright cut their price target on Inventiva from $14.00 to $13.00 and set a "buy" rating on the stock in a report on Tuesday, October 15th. Stifel Nicolaus cut their price target on Inventiva from $25.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, September 26th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Inventiva currently has a consensus rating of "Moderate Buy" and an average price target of $14.00.
Get Our Latest Stock Analysis on IVA
Inventiva Stock Performance
NASDAQ IVA traded down $0.02 during trading hours on Tuesday, reaching $2.68. The company's stock had a trading volume of 37,268 shares, compared to its average volume of 78,284. The business has a 50-day simple moving average of $2.29 and a 200 day simple moving average of $2.68. Inventiva has a 52 week low of $1.53 and a 52 week high of $4.75.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC purchased a new position in Inventiva S.A. (NASDAQ:IVA - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,490 shares of the company's stock, valued at approximately $38,000. Hedge funds and other institutional investors own 19.06% of the company's stock.
About Inventiva
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Further Reading
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
